ABSTRACT
We recently described X-linked acrogigantism (X-LAG), a condition of early childhood-onset pituitary gigantism associated with microduplications of the GPR101 receptor. The expression of GPR101 in hyperplastic pituitary regions and tumors in X-LAG patients, and GPR101's normally transient pituitary expression during fetal development, suggest a role in the regulation of growth. Nevertheless, little is still known about GPR101's physiological functions, especially during development. By using zebrafish models, we investigated the role of gpr101 during embryonic development and somatic growth. Transient ectopic gpr101 expression perturbed the embryonic body plan but did not affect growth. Loss of gpr101 led to a significant reduction in body size that was even more pronounced in the absence of maternal transcripts, as well as subfertility. These changes were accompanied by gastrulation and hypothalamic defects. In conclusion, both gpr101 loss- and gain-of-function affect, in different ways, fertility, embryonic patterning, growth and brain development.
Subject(s)
Acromegaly/genetics , Embryonic Development/genetics , Genetic Diseases, X-Linked/genetics , Gigantism/genetics , Receptors, G-Protein-Coupled/genetics , Zebrafish Proteins/genetics , Zebrafish/growth & development , Zebrafish/genetics , Acromegaly/complications , Animals , Female , Fertilization/genetics , Gastrulation/genetics , Gene Expression Regulation, Developmental , Gigantism/complications , Hypothalamus/pathology , Mutation/genetics , Ovum/metabolism , Receptors, G-Protein-Coupled/metabolism , Signal Transduction/genetics , Temperature , Transcriptome/genetics , Up-Regulation/genetics , Zebrafish Proteins/metabolism , Zygote/metabolismABSTRACT
Biochemical characterization of primary bilateral macronodular adrenocortical hyperplasia (PBMAH) by distinct plasma steroid profiles and its putative correlation to disease has not been previously studied. LC-MS/MS-based steroid profiling of 16 plasma steroids was applied to 36 subjects (22 females, 14 males) with PBMAH, 19 subjects (16 females, 3 males) with other forms of adrenal Cushing's syndrome (ACS), and an age and sex-matched control group. Germline ARMC5 sequencing was performed in all PBMAH cases. Compared to controls, PBMAH showed increased plasma 11-deoxycortisol, corticosterone, 11-deoxycorticosterone, 18-hydroxycortisol, and aldosterone, but lower progesterone, DHEA, and DHEA-S with distinct differences in subjects with and without pathogenic variants in ARMC5. Steroids that showed isolated differences included cortisol and 18-oxocortisol with higher (P < 0.05) concentrations in ACS than in controls and aldosterone with higher concentrations in PBMAH when compared to controls. Larger differences in PBMAH than with ACS were most clear for corticosterone, but there were also trends in this direction for 18-hydroxycortisol and aldosterone. Logistic regression analysis indicated four steroids - DHEA, 11-deoxycortisol, 18-oxocortisol, and corticosterone - with the most power for distinguishing the groups. Discriminant analyses with step-wise variable selection indicated correct classification of 95.2% of all subjects of the four groups using a panel of nine steroids; correct classification of subjects with and without germline variants in ARMC5 was achieved in 91.7% of subjects with PBMAH. Subjects with PBMAH show distinctive plasma steroid profiles that may offer a supplementary single-test alternative for screening purposes.
Subject(s)
Adrenal Gland Neoplasms/drug therapy , Cushing Syndrome/drug therapy , Steroids/therapeutic use , Tandem Mass Spectrometry/methods , Cross-Sectional Studies , Cushing Syndrome/pathology , Female , Humans , Male , Middle Aged , Steroids/pharmacologyABSTRACT
Pituitary adenomas in children and adolescents are rare tumors that often result from a tumor predisposition syndrome. Several inherited causes for pituitary adenomas have been identified in the last few years, including multiple endocrine neoplasia type 1 and 4, Carney's complex, Tuberous sclerosis, DICER1 syndrome, neurofibromatosis type 1, McCune Albright syndrome, familial isolated pituitary adenoma, and pituitary adenoma association due to defects in succinate dehydrogenase genes. Recently, our group discovered X-linked acrogigantism (X-LAG), a new pediatric disorder that is caused by an Xq26.3 genomic duplication (involving the GPR101 gene). Genes that predispose to pediatric Cushing disease, including CABLES1 and USP8, were also recently identified. Genetic screening and counseling of affected or at risk individuals is a key component of their comprehensive care. In this review, we provide an up-to-date discussion on the latest pediatric genetic discoveries associated with pituitary adenomas with a focus on familial syndromes.
ABSTRACT
The cAMP-dependent protein kinase (PKA) is an essential regulator of lipid and glucose metabolism that plays a critical role in energy homeostasis. The impact of diet on PKA signaling has not been defined, although perturbations in individual PKA subunits are associated with changes in adiposity, physical activity and energy intake in mice and humans. We hypothesized that a high fat diet (HFD) would elicit peripheral and central alterations in the PKA system that would differ depending on length of exposure to HFD; these differences could protect against or promote diet-induced obesity (DIO). 12-week-old C57Bl/6J mice were randomly assigned to a regular diet or HFD and weighed weekly throughout the feeding studies (4 days, 14 weeks; respectively), and during killing. PKA activity and subunit expression were measured in liver, gonadal adipose tissue (AT) and brain. Acute HFD-feeding suppressed basal hepatic PKA activity. In contrast, hepatic and hypothalamic PKA activities were significantly increased after chronic HFD-feeding. Changes in AT were more subtle, and overall, altered PKA regulation in response to chronic HFD exposure was more profound in female mice. The suppression of hepatic PKA activity after 4 day HFD-feeding was indicative of a protective peripheral effect against obesity in the context of overnutrition. In response to chronic HFD-feeding, and with the development of DIO, dysregulated hepatic and hypothalamic PKA signaling was a signature of obesity that is likely to promote further metabolic dysfunction in mice.
Subject(s)
Cyclic AMP-Dependent Protein Kinases/genetics , Diet, High-Fat/methods , Dietary Fats/adverse effects , Obesity/genetics , Protein Subunits/genetics , Adipose Tissue/enzymology , Adipose Tissue/pathology , Animals , Cyclic AMP/metabolism , Cyclic AMP Response Element-Binding Protein/genetics , Cyclic AMP Response Element-Binding Protein/metabolism , Cyclic AMP-Dependent Protein Kinases/metabolism , Diet, High-Fat/adverse effects , Energy Metabolism/genetics , Female , Gene Expression Regulation , Homeostasis , Hypothalamus/enzymology , Hypothalamus/pathology , Liver/enzymology , Liver/pathology , Male , Mice , Mice, Inbred C57BL , Obesity/enzymology , Obesity/etiology , Obesity/pathology , Organ Specificity , Ovary/enzymology , Ovary/pathology , Protein Subunits/metabolism , Sex Factors , Testis/enzymology , Testis/pathologyABSTRACT
CONTEXT: Endocrine problems are common in patients with Fanconi anemia (FA). About 80% of children and adults with FA have at least one endocrine abnormality, including short stature, GH deficiency, abnormal glucose or insulin metabolism, dyslipidemia, hypothyroidism, pubertal delay, hypogonadism, or impaired fertility. The goal of this report is to provide an overview of endocrine abnormalities and guidelines for routine screening and treatment to allow early diagnosis and timely intervention. EVIDENCE ACQUISITION: This work is based on a comprehensive literature review, including relevant articles published between 1971 and 2014, and proceedings of a Consensus Conference held by the Fanconi Anemia Research Fund in 2013. EVIDENCE SYNTHESIS: The panel of experts collected published evidence and discussed its relevance to reflect current information about the endocrine care of children and adults with FA before the Consensus Conference and through subsequent deliberations that led to the consensus. CONCLUSIONS: Individuals with FA should be routinely screened for endocrine abnormalities, including evaluation of growth; glucose, insulin, and lipid metabolism; thyroid function; puberty; gonadal function; and bone mineral metabolism. Inclusion of an endocrinologist as part of the multidisciplinary patient care team is key to providing comprehensive care for patients with FA.
Subject(s)
Endocrine System Diseases/diagnosis , Endocrine System Diseases/therapy , Fanconi Anemia/diagnosis , Fanconi Anemia/therapy , Mass Screening/standards , Practice Guidelines as Topic , Adult , Child , Endocrine System Diseases/etiology , Fanconi Anemia/complications , Glucose Metabolism Disorders/diagnosis , Glucose Metabolism Disorders/etiology , Glucose Metabolism Disorders/therapy , Growth Disorders/diagnosis , Growth Disorders/etiology , Growth Disorders/therapy , Human Growth Hormone/deficiency , Human Growth Hormone/therapeutic use , Humans , Malnutrition/diagnosis , Malnutrition/etiology , Malnutrition/therapy , Mass Screening/methods , Thinness/diagnosis , Thinness/etiology , Thinness/therapyABSTRACT
CONTEXT: Nuclear hormone receptors exert their transcriptional effects through shared cofactor molecules; thus, defects in such intermediate proteins may be associated with multiple hormone resistance. Microdeletion of small chromosomal segments results in hereditary or sporadic diseases by affecting expression of residing genes. OBJECTIVES: We describe a 7-yr-old boy with partial resistance to glucocorticoids, thyroid hormones, and possibly androgens. He was diagnosed as being in the autism spectrum disorder and had developmental delay and several facial morphological manifestations. We explored genes responsible for multiple hormone resistance of this case. RESULTS: We found in this patient an approximately 1.1-Mb heterozygous 16p11.2 microdeletion, which included an approximately 500-kb unique deletion along with the common, previously reported approximately 600-kb 16p11.2 microdeletion. The small interfering RNA-based screening revealed that knockdown of ZNF764, which is located in the deleted segment unique to our case, significantly reduced glucocorticoid-, androgen-, and thyroid hormone-induced transcriptional activity of their responsive genes in HeLa cells, whereas its overexpression enhanced their transcriptional activity. The activities of the estrogen and progesterone receptors, cAMP response element-binding protein, and p53 were not affected in these cells. ZNF764 (zinc finger protein 764) expression was reduced in the patient's peripheral blood mononuclear cells, whereas exogenously supplemented ZNF764 recovered responsiveness to glucocorticoids in the patient's Epstein-Barr virus-transformed lymphocytes. The effect of ZNF764 on the glucocorticoid receptor transcriptional activity was mediated through cooperation with a general nuclear hormone receptor coactivator, transcriptional intermediary factor 1. CONCLUSIONS: ZNF764 haploinsufficiency caused by microdeletion may be responsible for the partial multiple hormone resistance observed in our patient. ZNF764 appears to be involved in glucocorticoid, androgen, and thyroid hormone action.
Subject(s)
Androgens/pharmacology , Chromosome Deletion , Chromosomes, Human, Pair 16 , DNA-Binding Proteins/genetics , Glucocorticoids/pharmacology , Haploinsufficiency/genetics , Thyroid Hormone Resistance Syndrome/genetics , Zinc Fingers/genetics , Child , HCT116 Cells , Humans , Male , Receptors, Glucocorticoid/physiology , Transcription Factors/geneticsABSTRACT
The present study was undertaken in order to investigate the influence of gentamicin on plasma testosterone levels of healthy and with Freund's adjuvant arthritis rats. Gentamicin (40 mg/day for 4 days) induced significant decrease of testosterone levels in comparison with the control group (P<0.025). Intraperitoneal calcium administration (30 mg/ kg bw) prevented gentamicin effect and maintained testosterone levels to that of the control. Decreased testosterone levels were also observed in gentamicin received Freund's adjuvant arthritic rats, in the acute stage of the inflammatory disease (P<0.025), and in the acute stage of Freund's adjuvant arthritis (P<0.001). It is concluded that the administration of gentamicin decreases plasma testosterone levels without any effect on body and seminal vesicles weight. Calcium loading counteracts gentamicin reducing effect on plasma testosterone levels. Freund's adjuvant arthritis influences the function of body and seminal vesicles as it was shown by the reduction of testosterone levels, body and seminal vesicles weight during the acute phase of the inflammatory disease. In any case the effect was reversible.